LARGER VIALS = LARGER SAVINGS PER mg

CJC-1295 (No DAC) 5mg + Ipamorelin 5mg

CJC-1295 (No DAC) 5mg + Ipamorelin 5mg

$64.00
$64.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

CJC-1295 (No DAC) 5mg + Ipamorelin 5mg

CJC-1295 (No DAC) 5mg + Ipamorelin 5mg

$64.00
$64.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

CJC-1295 (no DAC) + Ipamorelin is a peptide blend combining a growth hormone–releasing hormone (GHRH) analog with a selective growth hormone secretagogue receptor (GHSR) agonist. This combination has been studied for its synergistic ability to increase pulsatile growth hormone secretion, thereby influencing IGF-1 levels, tissue repair, and metabolic function while minimizing off-target hormonal effects.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

This product is a research peptide blend of CJC-1295 (No DAC, 5 mg) and Ipamorelin (5 mg). Both peptides act as growth hormone (GH) secretagogues but through complementary mechanisms:

  • CJC-1295 (No DAC): A short-acting analogue of growth hormone–releasing hormone (GHRH) that increases pituitary GH release in a pulsatile manner, mimicking natural physiology.
  • Ipamorelin: A selective ghrelin receptor (GHS-R1a) agonist that stimulates GH release without significantly affecting cortisol or prolactin.

Together, this combination produces a synergistic increase in GH pulses and downstream insulin-like growth factor 1 (IGF-1) secretion, with potential implications for muscle growth, fat metabolism, recovery, and regenerative research.

Mechanism of Action

  • CJC-1295 (No DAC): Binds GHRH receptors on pituitary somatotrophs → increases GH pulse amplitude and frequency.
  • Ipamorelin: Binds ghrelin receptors → stimulates GH release through a distinct but complementary pathway.
  • Synergy: When co-administered, these peptides amplify each other’s effects, producing higher and more sustained GH pulses than either peptide alone.

Research

Growth Hormone & IGF-1 Elevation

  • CJC-1295 No DAC promotes physiologic GH pulsatility, while Ipamorelin adds an additional stimulatory effect.
  • Combined, they yield greater GH peaks and IGF-1 elevation, supporting muscle, bone, and connective tissue metabolism in preclinical studies.

Muscle & Body Composition

Research suggests this dual approach may enhance:

  • Muscle protein synthesis
  • Fat metabolism (lipolysis)
  • Recovery after injury or exercise

Regenerative & Anti-Aging Potential

GH and IGF-1 pathways are linked to:

  • Improved skin elasticity
  • Enhanced joint and connective tissue repair
  • Better sleep quality and recovery

Safety Profile

  • CJC-1295 (No DAC): Short half-life (~30 minutes), minimizing prolonged GH elevation.
  • Ipamorelin: Highly selective, with minimal impact on cortisol or prolactin compared to older GHRPs (e.g., GHRP-6).
  • Reported side effects are limited in preclinical models, but controlled human data remain sparse.

Summary

The CJC-1295 (No DAC) + Ipamorelin blend provides a two-pathway stimulation of GH release:

  • CJC-1295 No DAC: Enhances natural GH pulses
  • Ipamorelin: Selectively boosts GH via ghrelin receptor activation
  • Combined effect: Greater GH/IGF-1 elevation than either peptide alone

This synergistic action makes the blend a promising candidate for research into muscle growth, fat metabolism, tissue repair, and age-related GH decline.

This peptide blend is provided as a lyophilized powder (5 mg CJC-1295 No DAC + 5 mg Ipamorelin). Store vials at 2–8 °C in a sealed container, protected from light and moisture. For long-term storage, keep unopened vials at −20 °C. After reconstitution, prepare solutions under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Teichman SL, et al. Prolonged GH and IGF-1 stimulation with CJC-1295 in humans. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1536

2. Rahim A, et al. The effects of a GHRH analogue on GH pulsatility. Eur J Endocrinol. 2000;143(2):201–210. doi:10.1530/eje.0.1430201

3. Smith RG, et al. Peptidyl growth hormone secretagogues and their therapeutic potential. Endocr Rev. 1997;18(5):621–645. doi:10.1210/edrv.18.5.0318

4. Bowers CY. Synergistic release of GH by GHRH and GHRPs in humans. Endocrine. 1998;8(1):29–32. doi:10.1385/ENDO:8:1:29

5. Fairhall KM, et al. GH secretagogues and their effects on pulsatile GH release. Clin Endocrinol (Oxf). 2003;59(4):443–449. doi:10.1046/j.1365-2265.2003.01874.x

6. Veldhuis JD, et al. Neuroendocrine regulation of GH secretion in humans. Endocr Rev. 1992;21(1):1–27. doi:10.1210/edrv.21.1.0457

7. Kanaley JA, Weltman JY, Veldhuis JD. GH pulsatility with exercise and secretagogues. J Appl Physiol. 1997;83(3):947–955. doi:10.1152/jappl.1997.83.3.947

8. Walker RF, et al. Growth hormone-releasing peptides: physiological and pharmacological properties. Growth Horm IGF Res. 1994;4(1):42–49. doi:10.1016/S1096-6374(05)80006-7

9. Nass R, et al. The ghrelin receptor agonist Ipamorelin stimulates GH release in humans. J Clin Endocrinol Metab. 2008;93(1):399–405. doi:10.1210/jc.2007-1512

10. Barkan AL. Restoration of GH pulsatility in aging: implications for GHRH and GHRP combinations. Front Horm Res. 2005;33:64–82. doi:10.1159/000084687